In recent years, the Nuclear medicine market has undergone many changes. The medical specialty, not well known to the general public, is gaining more and more space as an important tool in cancer treatment.
According to MEDraysintell (a strategic intelligence company in the area of Nuclear medicine) a range of new radiopharmaceuticals will enter the market in the coming years, fueling the growth of the global Nuclear medicine market, which was valued at about $6 billion in 2019 and is expected to reach $30 billion by 2030. Radioisotope therapy accounted for 20% of the global Nuclear medicine market in 2019 and is expected to reach ~70% by 2030.
